eras-601,cetuximab,pembrolizumab
merck,eli lilly,erasca
['flagshp-1', 'ct184', 'cetuximab', 'eras-601', 'solid tumor']
#aacr23 | section 45 | tues
ct184 - preliminary dose escalation results of eras-601 in combination with cetuximab in flagshp-1: a phase i study of eras-601, a potent and selective shp2 inhibitor, in patients with previously treated advanced or metastatic solid tumors 
The official Twitter account for Mass General Cancer Center, a member of Mass General Brigham.